Greenwich LifeSciences has announced a significant expansion of its Flamingo-01 clinical trial, extending its research efforts into Belgium. The move marks a strategic step in the company’s ongoing commitment to advancing innovative treatments in oncology, broadening the trial’s geographic reach and patient diversity. This development was confirmed in a recent statement, highlighting Greenwich LifeSciences’ dedication to accelerating clinical progress and generating robust data that could potentially benefit cancer patients worldwide.
Greenwich LifeSciences Extends Flamingo-01 Trial to Belgium Enhancing European Research Collaboration
Greenwich LifeSciences has announced a strategic extension of its Flamingo-01 clinical trial into Belgium, marking a significant step forward in its commitment to advancing innovative therapies across Europe. This expansion enables the trial to leverage Belgium’s robust medical infrastructure and experienced research institutions, thereby…
—-
Author : Victoria Jones
Publish date : 2025-10-02 14:55:00
Copyright for syndicated content belongs to the linked Source.
—-
1 – 2 – 3 – 4 – 5 – 6 – 7 – 8
